| Outcome Measures: |
Primary: Change in Glycosylated Haemoglobin (HbA1c), Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 16. The endpoint was evaluated based on data from the in-trial observation period. In-trial observation period was from date of randomisation and until last trial-related participant-site contact., Week 0, week 16 | Secondary: Change From Baseline in 1-hour PPG Increment, Change from baseline (week 0) in 1-hour postprandial glucose (PPG) increment was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact., Week 0, week 16|Change From Baseline in 1,5-anhydroglucitol, Change from baseline (week 0) in 1,5-anhydroglucitol was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact., Week 0, week 16|Change From Baseline in Fasting Plasma Glucose (FPG), Change from baseline (week 0) in fasting plasma glucose was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact., Week 0, week 16|Participants Who Achieved HbA1c <7.0% (53 mmol/L) (Yes/No), Number of participants reaching HbA1c \<7.0% (53 mmol/L) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact., 16 weeks after randomisation|Participants Who Achieved HbA1c <7.0% (53 mmol/L) Without Severe Hypoglycaemia Episodes (Yes/No), Number of participants reaching HbA1c \<7.0% (53 mmol/L) without severe hypoglycaemia episodes was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact., 16 weeks after randomisation|Change From Baseline (Week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour Postprandial Glucose (PPG [Meal Test]), Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour postprandial glucose (PPG \[meal test\]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal., Week 0, week 16|Change From Baseline (Week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour PPG Increment (Meal Test), Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour PPG increment (meal test) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal. PPG incremental value for each time point was derived as PPG value at that time point minus the preprandial glucose value., Week 0, week 16|Change From Baseline in Mean of the 7-9-7 Point Self-measured Plasma Glucose (SMPG) Profile, Change from baseline (week 0) in mean of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. 7-9-7 point SMPG was measured at the following mentioned time points: 1) Before breakfast, 2) 60 mins after the start of Breakfast, 3) Before lunch, 4) 60 mins after the start of lunch, 5) Before main evening meal, 6) 60 mins after the start of main evening meal, 7) At bedtime, 8) At 4 AM, 9) Before breakfast., Week 0, week 16|Change From Baseline of the 7-9-7 Point SMPG Profile: PPG (Mean, Breakfast, Lunch and Main Evening Meal), Change from baseline (week 0) in PPG (breakfast, lunch, main evening meal and mean over all meals) of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact., Week 0, week 16|Change From Baseline of the 7-9-7 Point SMPG Profile: PPG Increment (Mean, Breakfast, Lunch and Main Evening Meal), Change from baseline (week 0) in PPG increment (breakfast, lunch, main evening meal and mean over all meals) of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. PPG increment based on the 7-9-7-point profiles were derived separately for PG measurements made at 1 hour after main meals (breakfast, lunch and main evening meal). PPG incremental value for each time point was derived as PPG value at that time point minus the preprandial glucose value. In trial observation period was from date of randomisation and until last trial-related participant-site contact., Week 0, week 16|Change From Baseline of the 7-9-7 Point SMPG Profile: Fluctuation in 7-9-7 Point Profile, Fluctuation in 7-point SMPG profile was the average absolute difference from the mean of the SMPG profile. Reported results are fluctuation in the 7-9-7 point SMPG profile from baseline (week 0) after 16 weeks of randomisation (i.e., week 16). The results are presented as ratio to baseline. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact., Week 0, week 16|Change From Baseline of the 7-9-7 Point SMPG Profile: Nocturnal SMPG Measurements, Change from baseline (week 0) in nocturnal SMPG measurements was assessed by considering the differences between PG values available at bedtime, at 4 AM and the before breakfast value the following day: (4 AM PG value minus at bedtime PG value), (before breakfast PG value minus at bedtime PG value) and (before breakfast PG value minus 4 AM PG value). Change from baseline in nocturnal increments in SMPG measurements of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation and presented during three different time intervals as follows: 1) 04:00 to breakfast, 2) bedtime to 04:00, and 3) bedtime to breakfast. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact., Week 0, week 16|Participants Who Achieved Overall PPG (1 Hour) <7.8 mmol/L (140 mg/dL) (Yes/No), Participants reaching overall PPG (1 hour) ≤7.8 mmol/L \[140 mg/dL\] was evaluated after 16 weeks of randomisation. Participants without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact., 16 weeks after randomisation|Participants Who Achieved Overall PPG <7.8 mmol/L (140 mg/dL) Without Severe Hypoglycaemia Episodes (Yes/No), Participants reaching overall PPG (1 hour) ≤7.8 mmol/L \[140 mg/dL\] without severe hypoglycaemia episodes was evaluated after 16 weeks of randomisation. Participants without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact., 16 weeks after randomisation|Total Bolus Insulin Dose: in Units/Day, Total bolus insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., 16 weeks from randomisation|Total Bolus Insulin Dose: in Units/kg/Day, Total bolus insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., 16 weeks from randomisation|Total Basal Insulin Dose: in Units/Day, Total basal insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., 16 weeks from randomisation|Total Basal Insulin Dose: in Units/kg/Day, Total basal insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., 16 weeks from randomisation|Individual Meal Insulin Dose: in Units, Individual meal time bolus insulin dose (Units) for breakast, lunch and main evening meal was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., 16 weeks from randomisation|Individual Meal Insulin Dose: in Units/kg, Individual meal time bolus insulin dose (Units/kg) for breakast, lunch and main evening meal was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., 16 weeks from randomisation|Change From Baseline in Lipids-lipoproteins Profile (Total Cholesterol, High Density Lipoproteins, Low Density Lipoproteins) - Ratio to Baseline, Reported results are lipids-lipoproteins (total cholesterol, high density lipoproteins, low density lipoproteins) values are given as ratio to baseline (week 0) after 16 weeks. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact., Week 0, week 16|Number of Treatment Emergent Adverse Events, Number of treatment emergent adverse events were recorded from week 0 to week 16. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Weeks 0-16|Number of Treatment Emergent Injection Site Reactions, Number of treatment emergent injection site reactions were recorded from week 0 to week 16. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Weeks 0-16|Number of Treatment Emergent Hypoglycaemic Episodes (Hypos) According to the American Diabetes Association (ADA) and Novo Nordisk (NN) Definition: Overall, ADA classification of hypos: 1. Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level. 2. Documented symptomatic: PG ≤3.9 mmol/L with symptoms. 3. Asymptomatic: PG ≤3.9 mmol/L without symptoms. 4. Probable symptomatic: No measurement with symptoms. 5. Pseudo: PG \>3.9 mmol/L with symptoms. 6. Unclassifiable. NN classification of hypos: 1. BG confirmed: PG \<3.1 mmol/L with/without symptoms. 2. Severe or BG confirmed symptomatic: Severe as per ADA and BG confirmed by PG \<3.1 mmol/L with symptoms. 3. Severe or BG confirmed: Severe as per ADA and BG confirmed by PG \<3.1 mmol/L with/without symptoms. 4. Unclassifiable. Not able to self treat-unclassifiable: Not able to self treat but not classifiable as severe hypoglycaemia., Weeks 0-16|Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Daytime Hypoglycaemic Episodes (06:00-00:00 - Inclusive), Number of treatment emergent day time hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 06:00 and 00:00 (both included). The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Weeks 0-16|Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Nocturnal Hypoglycaemic Episodes (00:01-05:59 - Inclusive), Number of treatment emergent nocturnal hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 00:01 and 05:59 (both included). The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Weeks 0-16|Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 1 Hour After Start of the Meal, Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 1 hour after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Weeks 0-16|Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 2 Hours After Start of the Meal, Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 2 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Weeks 0-16|Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 4 Hours After Start of the Meal, Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 4 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Weeks 0-16|Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes Occurring Between 2 to 4 Hours After Start of the Meal, Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 2 to 4 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Weeks 0-16|Change From Baseline in Physical Examination, Participants with physical examination findings, normal, abnormal NCS (non- clinically significant) and abnormal CS (clinically significant) at baseline (week 0) and week 16 presented. Results are based on the data from the on-treatment observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. Results are presented for the following examinations: 1) Cardiovascular system 2) Central \& Peripheral nervous system 3) Gastrointestinal system incl. mouth 4) Head, ears, eyes, nose, throat and neck 5) Musculoskeletal system 6) Respiratory system 7) Skin, Week 0, week 16|Change From Baseline in Vital Signs: Systolic and Diastolic Blood Presure, Change in vital signs - systolic and diastolic blood pressure from baseline (week 0) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Vital Signs: Pulse, Change in vital signs - pulse from baseline (week 0) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Electrocardiogram (ECG), Changes in electrocardiogram (ECG) from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Fundoscopy/Fundus Photography, Changes in fundoscopy/fundus photography from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Haematology - Haematocrit, Changes in haematology - haematocrit from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Haematology - Haemoglobin, Changes in haematology - haemoglobin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Haematology - Leukocytes, Changes in haematology - leukocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Haematology - Thrombocytes, Changes in haematology - thrombocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Haematology - Erythrocytes, Changes in haematology - erythrocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Biochemistry - Alanine Aminotransferase (ALT), Changes in biochemistry - alanine aminotransferase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Biochemistry - Alkaline Phosphatase, Changes in biochemistry - alkaline phosphatase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Biochemistry - Aspartate Aminotransferase (AST), Changes in biochemistry - aspratate aminotransferase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Biochemistry - Albumin, Changes in biochemistry - albumin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Biochemistry - Creatinine, Changes in biochemistry - creatinine from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Biochemistry - Potassium, Changes in biochemistry - potassium from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Biochemistry - Sodium, Changes in biochemistry - sodium from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Biochemistry - Total Bilirubin, Changes in biochemistry - total bilirubin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Biochemistry - Total Protein, Changes in biochemistry - total protein from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Body Weight, Changes in body weight from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16|Change From Baseline in Body Mass Index (BMI), Change in the body mass index (BMI) from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment., Week 0, week 16
|
| Locations: |
Novo Nordisk Investigational Site, Concord, California, 94520, United States|Novo Nordisk Investigational Site, Fresno, California, 93720, United States|Novo Nordisk Investigational Site, Fullerton, California, 92835, United States|Novo Nordisk Investigational Site, Lancaster, California, 93534, United States|Novo Nordisk Investigational Site, Norco, California, 92860, United States|Novo Nordisk Investigational Site, Sacramento, California, 95821, United States|Novo Nordisk Investigational Site, Ventura, California, 93003, United States|Novo Nordisk Investigational Site, Walnut Creek, California, 94598, United States|Novo Nordisk Investigational Site, Denver, Colorado, 80246, United States|Novo Nordisk Investigational Site, Golden, Colorado, 80401, United States|Novo Nordisk Investigational Site, Waterbury, Connecticut, 06708, United States|Novo Nordisk Investigational Site, Boynton Beach, Florida, 33472, United States|Novo Nordisk Investigational Site, Bradenton, Florida, 34201, United States|Novo Nordisk Investigational Site, Fort Lauderdale, Florida, 33312, United States|Novo Nordisk Investigational Site, Miami, Florida, 33174, United States|Novo Nordisk Investigational Site, Tampa, Florida, 33634, United States|Novo Nordisk Investigational Site, Alpharetta, Georgia, 30022, United States|Novo Nordisk Investigational Site, Lawrenceville, Georgia, 30046, United States|Novo Nordisk Investigational Site, Roswell, Georgia, 30076, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, 96814, United States|Novo Nordisk Investigational Site, Chicago, Illinois, 60611, United States|Novo Nordisk Investigational Site, Peoria, Illinois, 61603, United States|Novo Nordisk Investigational Site, Springfield, Illinois, 62711, United States|Novo Nordisk Investigational Site, Valparaiso, Indiana, 46383, United States|Novo Nordisk Investigational Site, West Des Moines, Iowa, 50266, United States|Novo Nordisk Investigational Site, Topeka, Kansas, 66606, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, 40502, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, 40503, United States|Novo Nordisk Investigational Site, Rockville, Maryland, 20852, United States|Novo Nordisk Investigational Site, Waltham, Massachusetts, 02453, United States|Novo Nordisk Investigational Site, Worcester, Massachusetts, 01655, United States|Novo Nordisk Investigational Site, Henderson, Nevada, 89052-2649, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, 89148, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, 03063, United States|Novo Nordisk Investigational Site, Northport, New York, 11768, United States|Novo Nordisk Investigational Site, West Seneca, New York, 14224, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, 28803, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, 27514, United States|Novo Nordisk Investigational Site, Mentor, Ohio, 44060, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, 73104-5020, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, 19140, United States|Novo Nordisk Investigational Site, Greenville, South Carolina, 29605-4254, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, 37404, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, 37411, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, 37212, United States|Novo Nordisk Investigational Site, Amarillo, Texas, 79106, United States|Novo Nordisk Investigational Site, Austin, Texas, 78731, United States|Novo Nordisk Investigational Site, Austin, Texas, 78749, United States|Novo Nordisk Investigational Site, Beaumont, Texas, 77701, United States|Novo Nordisk Investigational Site, Dallas, Texas, 75226, United States|Novo Nordisk Investigational Site, Dallas, Texas, 75230, United States|Novo Nordisk Investigational Site, Dallas, Texas, 75231, United States|Novo Nordisk Investigational Site, Longview, Texas, 75605, United States|Novo Nordisk Investigational Site, Pearland, Texas, 77584, United States|Novo Nordisk Investigational Site, Round Rock, Texas, 78681, United States|Novo Nordisk Investigational Site, Ogden, Utah, 84405, United States|Novo Nordisk Investigational Site, Bennington, Vermont, 05201, United States|Novo Nordisk Investigational Site, South Burlington, Vermont, 05403, United States|Novo Nordisk Investigational Site, Chesapeake, Virginia, 23321, United States|Novo Nordisk Investigational Site, Winchester, Virginia, 22601-3834, United States|Novo Nordisk Investigational Site, Olympia, Washington, 98502, United States|Novo Nordisk Investigational Site, Seattle, Washington, 98105, United States|Novo Nordisk Investigational Site, Spokane, Washington, 99201, United States|Novo Nordisk Investigational Site, Green Bay, Wisconsin, 54303, United States|Novo Nordisk Investigational Site, Caba, C1060ABA, Argentina|Novo Nordisk Investigational Site, Caba, C1440AAD, Argentina|Novo Nordisk Investigational Site, Cordoba, 5000, Argentina|Novo Nordisk Investigational Site, Córdoba, 5008, Argentina|Novo Nordisk Investigational Site, Kozloduy, 3320, Bulgaria|Novo Nordisk Investigational Site, Razgrad, 7200, Bulgaria|Novo Nordisk Investigational Site, Sofia, 1233, Bulgaria|Novo Nordisk Investigational Site, Sofia, 1618, Bulgaria|Novo Nordisk Investigational Site, Edmonton, Alberta, T6G 2E1, Canada|Novo Nordisk Investigational Site, Victoria, British Columbia, V8V 4A1, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, B3H 2Y9, Canada|Novo Nordisk Investigational Site, Barrie, Ontario, L4N 7L3, Canada|Novo Nordisk Investigational Site, Concord, Ontario, L4K 4M2, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, M9R 4E1, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, L8M 1K7, Canada|Novo Nordisk Investigational Site, Newmarket, Ontario, L3Y 5G8, Canada|Novo Nordisk Investigational Site, Thunder Bay, Ontario, P7A 4V7, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, M4G 3E8, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, H4T 1Z9, Canada|Novo Nordisk Investigational Site, Karlovac, 47000, Croatia|Novo Nordisk Investigational Site, Osijek, 31 000, Croatia|Novo Nordisk Investigational Site, Varazdin, 42 000, Croatia|Novo Nordisk Investigational Site, Zagreb, 10 000, Croatia|Novo Nordisk Investigational Site, Hradec Kralove, 500 05, Czechia|Novo Nordisk Investigational Site, Plzen, 30100, Czechia|Novo Nordisk Investigational Site, Plzen, 32600, Czechia|Novo Nordisk Investigational Site, Trutnov, 541 01, Czechia|Novo Nordisk Investigational Site, Dresden, 01219, Germany|Novo Nordisk Investigational Site, Essen, 45136, Germany|Novo Nordisk Investigational Site, Falkensee, 14612, Germany|Novo Nordisk Investigational Site, Lingen, 49808, Germany|Novo Nordisk Investigational Site, Münster, 48145, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, 66386, Germany|Novo Nordisk Investigational Site, Schweinfurt, 97421, Germany|Novo Nordisk Investigational Site, Athens, 115 25, Greece|Novo Nordisk Investigational Site, Athens, GR-11527, Greece|Novo Nordisk Investigational Site, Ioannina, 45500, Greece|Novo Nordisk Investigational Site, Larissa, GR-41110, Greece|Novo Nordisk Investigational Site, Thessaloniki, GR-54636, Greece|Novo Nordisk Investigational Site, Thessaloniki, GR-54642, Greece|Novo Nordisk Investigational Site, Thessaloniki, GR-54643, Greece|Novo Nordisk Investigational Site, Thessaloniki, GR-57001, Greece|Novo Nordisk Investigational Site, Catanzaro, 88100, Italy|Novo Nordisk Investigational Site, Chieti, 66100, Italy|Novo Nordisk Investigational Site, Cittadella (PD), 35013, Italy|Novo Nordisk Investigational Site, Milano (MI), 20132, Italy|Novo Nordisk Investigational Site, Olbia, 07026, Italy|Novo Nordisk Investigational Site, Palermo, 90129, Italy|Novo Nordisk Investigational Site, Bucheon, 14647, Korea, Republic of|Novo Nordisk Investigational Site, Daegu, 42472, Korea, Republic of|Novo Nordisk Investigational Site, Seongnam-si, 463-707, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, 02447, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, 03080, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, 04516, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, 06351, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, 08308, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, 137-701, Korea, Republic of|Novo Nordisk Investigational Site, Wonju, 26426, Korea, Republic of|Novo Nordisk Investigational Site, Bialystok, 15-435, Poland|Novo Nordisk Investigational Site, Skorzewo, 60-185, Poland|Novo Nordisk Investigational Site, Warsaw, 00-465, Poland|Novo Nordisk Investigational Site, Warsaw, 02-793, Poland|Novo Nordisk Investigational Site, Warszawa, 02-507, Poland|Novo Nordisk Investigational Site, Wroclaw, 50-381, Poland|Novo Nordisk Investigational Site, Ponce, 00716, Puerto Rico|Novo Nordisk Investigational Site, Baia Mare, Maramures, 430222, Romania|Novo Nordisk Investigational Site, Tirgu Mures, Mures, 540142, Romania|Novo Nordisk Investigational Site, Timisoara, Timis, 300125, Romania|Novo Nordisk Investigational Site, Brasov, 500101, Romania|Novo Nordisk Investigational Site, Brasov, 500283, Romania|Novo Nordisk Investigational Site, Bucharest, 13682, Romania|Novo Nordisk Investigational Site, Arkhangelsk, 163045, Russian Federation|Novo Nordisk Investigational Site, Kazan, 420073, Russian Federation|Novo Nordisk Investigational Site, Moscow, 123448, Russian Federation|Novo Nordisk Investigational Site, Penza, 440026, Russian Federation|Novo Nordisk Investigational Site, Saint Petersburg, 194291, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, 194356, Russian Federation|Novo Nordisk Investigational Site, Tumen, 625023, Russian Federation|Novo Nordisk Investigational Site, Voronezh, 394018, Russian Federation|Novo Nordisk Investigational Site, Belgrade, 11000, Serbia|Novo Nordisk Investigational Site, Kragujevac, 34000, Serbia|Novo Nordisk Investigational Site, Nis, 18000, Serbia|Novo Nordisk Investigational Site, Novi Sad, 21000, Serbia|Novo Nordisk Investigational Site, Zajecar, 19000, Serbia|Novo Nordisk Investigational Site, Kosice, 040 01, Slovakia|Novo Nordisk Investigational Site, Kysucke Nove Mesto, 024 01, Slovakia|Novo Nordisk Investigational Site, Lubochna, 03491, Slovakia|Novo Nordisk Investigational Site, Lucenec, 984 01, Slovakia|Novo Nordisk Investigational Site, Zilina, 01001, Slovakia|Novo Nordisk Investigational Site, Alcobendas, 28100, Spain|Novo Nordisk Investigational Site, Almería, 04001, Spain|Novo Nordisk Investigational Site, Girona, 17007, Spain|Novo Nordisk Investigational Site, La Coruña, 15006, Spain|Novo Nordisk Investigational Site, Pozuelo de Alarcon, 28223, Spain|Novo Nordisk Investigational Site, Sabadell, 08208, Spain|Novo Nordisk Investigational Site, Sevilla, 41003, Spain|Novo Nordisk Investigational Site, Sevilla, 41010, Spain|Novo Nordisk Investigational Site, Dnipro, 49038, Ukraine|Novo Nordisk Investigational Site, Kharkiv, 61000, Ukraine|Novo Nordisk Investigational Site, Kyiv, 03049, Ukraine|Novo Nordisk Investigational Site, Lviv, 79010, Ukraine|Novo Nordisk Investigational Site, Ternopil, 46002, Ukraine|Novo Nordisk Investigational Site, Vinnytsia, 21010, Ukraine
|
